Safety of methylene blue dye for lymphatic mapping in patients taking selective serotonin reuptake inhibitors

Miraj G. Shah-Khan, Jenna Lovely, Amy C Degnim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Methylene blue dye has an important role in lymphatic mapping for sentinel lymph node surgery. A recent safety announcement from the US Food and Drug Administration warned physicians about possible serious central nervous system reactions in patients on serotonergic medications who received intravenous methylene blue for the identification of parathyroid glands. This report summarizes evidence from the Food and Drug Administration's announcement and methylene blue pharmacokinetics. The authors conclude that the use of methylene blue dye at low doses for lymphatic mapping likely carries very little risk for serotonin neurotoxicity, although breast surgeons should be aware of this potential complication in the event of mental status or neuromuscular changes in patients after lymphatic mapping.

Original languageEnglish (US)
Pages (from-to)798-799
Number of pages2
JournalAmerican Journal of Surgery
Volume204
Issue number5
DOIs
StatePublished - Nov 2012

Fingerprint

Methylene Blue
Serotonin Uptake Inhibitors
Coloring Agents
Safety
United States Food and Drug Administration
Parathyroid Glands
Serotonin
Breast
Central Nervous System
Pharmacokinetics
Physicians

Keywords

  • Methylene blue dye
  • Selective serotonin reuptake inhibitors

ASJC Scopus subject areas

  • Surgery

Cite this

Safety of methylene blue dye for lymphatic mapping in patients taking selective serotonin reuptake inhibitors. / Shah-Khan, Miraj G.; Lovely, Jenna; Degnim, Amy C.

In: American Journal of Surgery, Vol. 204, No. 5, 11.2012, p. 798-799.

Research output: Contribution to journalArticle

@article{f5b472a1336344a0a05271feecf20d71,
title = "Safety of methylene blue dye for lymphatic mapping in patients taking selective serotonin reuptake inhibitors",
abstract = "Methylene blue dye has an important role in lymphatic mapping for sentinel lymph node surgery. A recent safety announcement from the US Food and Drug Administration warned physicians about possible serious central nervous system reactions in patients on serotonergic medications who received intravenous methylene blue for the identification of parathyroid glands. This report summarizes evidence from the Food and Drug Administration's announcement and methylene blue pharmacokinetics. The authors conclude that the use of methylene blue dye at low doses for lymphatic mapping likely carries very little risk for serotonin neurotoxicity, although breast surgeons should be aware of this potential complication in the event of mental status or neuromuscular changes in patients after lymphatic mapping.",
keywords = "Methylene blue dye, Selective serotonin reuptake inhibitors",
author = "Shah-Khan, {Miraj G.} and Jenna Lovely and Degnim, {Amy C}",
year = "2012",
month = "11",
doi = "10.1016/j.amjsurg.2012.02.004",
language = "English (US)",
volume = "204",
pages = "798--799",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Safety of methylene blue dye for lymphatic mapping in patients taking selective serotonin reuptake inhibitors

AU - Shah-Khan, Miraj G.

AU - Lovely, Jenna

AU - Degnim, Amy C

PY - 2012/11

Y1 - 2012/11

N2 - Methylene blue dye has an important role in lymphatic mapping for sentinel lymph node surgery. A recent safety announcement from the US Food and Drug Administration warned physicians about possible serious central nervous system reactions in patients on serotonergic medications who received intravenous methylene blue for the identification of parathyroid glands. This report summarizes evidence from the Food and Drug Administration's announcement and methylene blue pharmacokinetics. The authors conclude that the use of methylene blue dye at low doses for lymphatic mapping likely carries very little risk for serotonin neurotoxicity, although breast surgeons should be aware of this potential complication in the event of mental status or neuromuscular changes in patients after lymphatic mapping.

AB - Methylene blue dye has an important role in lymphatic mapping for sentinel lymph node surgery. A recent safety announcement from the US Food and Drug Administration warned physicians about possible serious central nervous system reactions in patients on serotonergic medications who received intravenous methylene blue for the identification of parathyroid glands. This report summarizes evidence from the Food and Drug Administration's announcement and methylene blue pharmacokinetics. The authors conclude that the use of methylene blue dye at low doses for lymphatic mapping likely carries very little risk for serotonin neurotoxicity, although breast surgeons should be aware of this potential complication in the event of mental status or neuromuscular changes in patients after lymphatic mapping.

KW - Methylene blue dye

KW - Selective serotonin reuptake inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84868549951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868549951&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2012.02.004

DO - 10.1016/j.amjsurg.2012.02.004

M3 - Article

VL - 204

SP - 798

EP - 799

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 5

ER -